SCHEMBL6729004

SCHEMBL6729004

Oc1nc(NCc2ccco2)nc(Nc2ccc3ncsc3c2)n1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.53
KMT2A Q03164 3/20 0.53
RECQL P46063 1/20 0.53
KCNH3 Q9ULD8 3/20 0.52
KDR P35968 4/20 0.46
INSR P06213 1/20 0.46
CSF1R P07333 1/20 0.46
PDGFRB P09619 1/20 0.46
PDGFRA P16234 1/20 0.46
TEK Q02763 1/20 0.46
MAPK1 P28482 4/20 0.46
SYK P43405 1/20 0.46
NPSR1 Q6W5P4 3/20 0.45
ALDH1A1 P00352 2/20 0.45
MEN1 O00255 1/20 0.45
EGFR P00533 1/20 0.45
TSHR P16473 1/20 0.44
SOS1 Q07889 3/20 0.44
USP2 O75604 1/20 0.43
LMNA P02545 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1391930 0.86 MAPT (0.64) MAPTKMT2ARECQLKCNH3KDR
SCHEMBL6730170 0.83 KCNH3 (0.53) KCNH3KDRINSRCSF1RPDGFRB
SCHEMBL6315627 0.83 KDR (0.64) KCNH3KDRINSRCSF1RPDGFRB
SCHEMBL6400760 0.80 KDR (0.47) KMT2AKCNH3KDRINSRCSF1R
SCHEMBL6397615 0.80 KDR (0.53) KCNH3KDRINSRCSF1RPDGFRB
SCHEMBL6395906 0.80 KDR (0.60) KDRINSRCSF1RPDGFRBPDGFRA
SCHEMBL6400459 0.79 PFKFB3 (0.52) KCNH3KDRINSRCSF1RPDGFRB
SCHEMBL6729137 0.79 KDR (0.51) KMT2AKDRINSRCSF1RPDGFRB
SCHEMBL6406493 0.79 KDR (0.51) MAPTKDRINSRCSF1RPDGFRB
SCHEMBL6405778 0.79 KDR (0.52) MAPTKMT2AKDRINSRCSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040110758-A1 4,6-Diaminosubstituted-2-[oxy or aminoxy]-[1,3,5]triazines as protein tyrosine kinase inhibitors 3-DIMENSIONAL PHARMACEUTICALS, INC. 2004-06-10 US claimed
US-20040110758-A1 4,6-Diaminosubstituted-2-[oxy or aminoxy]-[1,3,5]triazines as protein tyrosine kinase inhibitors 3-DIMENSIONAL PHARMACEUTICALS, INC. 2004-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110758-A1 4,6-Diaminosubstituted-2-[oxy or aminoxy]-[1,3,5]triazines as protein tyrosine kinase inhibitors TIE1, KDR, FLT1 MAPT 627/4885KMT2A 428/4885RECQL 1230/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.